VIR
NASDAQVir Biotechnology Inc.
Price$10.21+0.04 (+0.34%)
01:45 PM07:45 PM
News · 26 weeks73+100%
2025-11-022026-04-26
Mix4990d
- Insider19(39%)
- SEC Filings15(31%)
- Other6(12%)
- Earnings5(10%)
- Offering3(6%)
- Analyst1(2%)
Latest news
25 items- INSIDERPresident and CEO De Backer Marianne disposed of 233,532 shares and acquired 233,532 shares, decreasing direct ownership by 25% to 714,613 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- PRVir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsVir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas
- SECSEC Form DEFA14A filed by Vir Biotechnology Inc.DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECSEC Form DEF 14A filed by Vir Biotechnology Inc.DEF 14A - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, and Astellas obtaining exclusive rights to commercialize VIR-5500 ex-U.S. Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The collaboration aims to accelerate the development of VIR-5500, a prostate-specific membrane antigen (PSMA)-targe
- PRVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate CancerPhase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) Dose-expansion builds on promising Phase 1 monotherapy dose-escalation data in mCRPC presented in February 2026 Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for metastatic prostate cancer (NCT05997615). The Phase 1 trial is measuring
- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- INSIDERSEC Form 4 filed by De Backer Marianne4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSEC Form 4 filed by Sato Vicki L4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vir Biotechnology Inc.SCHEDULE 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
- INSIDERSEC Form 4 filed by Sabatini Brent4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSEC Form 4 filed by O'Byrne Jason4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- PRNext-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and immunotherapy[1]. Yet cancer remains the second-leading cause of death worldwide, with an estimated 2.1 million new diagnoses expected in 2026 alone and mortality rates still climbing among younger populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ:ONCY), Vir Biotechnology (NASDAQ:VIR), Iovance Biotherapeutics (NASDAQ:IOVA), C4 Therapeutic
- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vir Biotechnology Inc.SCHEDULE 13D/A - Vir Biotechnology, Inc. (0001706431) (Subject)
- INSIDERDirector Sato Vicki L sold $209,181 worth of shares (22,000 units at $9.51), decreasing direct ownership by 2% to 1,122,391 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECSEC Form 144 filed by Vir Biotechnology Inc.144 - Vir Biotechnology, Inc. (0001706431) (Subject)
- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECSEC Form 424B5 filed by Vir Biotechnology Inc.424B5 - Vir Biotechnology, Inc. (0001706431) (Filer)
- INSIDERDirector Sato Vicki L exercised 42,377 shares at a strike of $1.49 and sold $413,366 worth of shares (42,377 units at $9.75) (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSVP, Chief Accounting Officer Sabatini Brent sold $13,632 worth of Common Stock (1,430 units at $9.53), decreasing direct ownership by 2% to 69,613 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDEREVP & Chief Financial Officer O'Byrne Jason sold $15,576 worth of Common Stock (1,634 units at $9.53), decreasing direct ownership by 0.99% to 162,615 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDEREVP and Chief Medical Officer Eisner Mark sold $33,955 worth of shares (3,505 units at $9.69), decreasing direct ownership by 2% to 154,024 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDEREVP, General Counsel, Corp Sec De Verneuil Vanina sold $164,247 worth of Common Stock (16,817 units at $9.77), decreasing direct ownership by 13% to 112,982 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
VIR FAQ
7 questionsWhat does Vir Biotechnology Inc. do?
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration...Where does VIR stock trade?
Vir Biotechnology Inc. (VIR) is listed on NASDAQ.What sector and industry is VIR in?
Vir Biotechnology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vir Biotechnology Inc. go public?
Vir Biotechnology Inc. (VIR) completed its IPO in 2019.What are analysts saying about VIR?
Vir Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1900.00 price target on 2026-02-24. Recent price targets range from $900.00 to $3400.00.What companies are similar to VIR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VIR side-by-side with any of them on Quantisnow.How can I track VIR on Quantisnow?
Quantisnow aggregates Vir Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIR to receive live email and push alerts on every new disclosure.